Dr Motzer from MSKCC presents data affirming the benefit of nivo/cabo over the longer term

Question: does the good risk RCC data give us the opportunity to either 1) de-escalate to single agent or 2) focus on dual I/O with a goal of achieving more durable response, eventually going off tx

#gu25

A new addition to standards in *pure seminoma* for patients *motivated to avoid radiation and chemotherapy* and have the ability to travel to HIGH VOLUME centers, as presented by Dr Heidenrich and discussed by Dr Cary. #gu25

In less experienced hands, this will add surgical morbidity to chemo

Fantastic review by @tiansterzhangmd.bsky.social of #gu25 kidney cancer abstracts

This is not the headline. Real headline: this regimen does not improve OS, and there is no reason to add the treatment related and $$$ toxicity of this triplet.

- If you need a quicker response, use nivo+cabo OR axi+pembro
- If you are going for finite tx with durable response, use ipi+nivo

#gu25

Useful illustrative reminder from Dr Devaki Shilpa Surasi about limitations of PSMA imaging and utility of conventional imaging in assessing prostate cancer post therapy #GU25

Dr David Fisher - STOPCAP meta-analyses, mHSPC younger, higher BMI, low volume disease, may benefit more from ARPIs. ARPI and docetaxel doublets effective in high-volume, synchronous disease. In discussion, Dr Tanya Doruff provided a schema in how we might choose initial therapy.

Provocative data from Dr Soumyajit Roy regarding RT+ADT versus RP in high risk prostate cancer